Bayer (FRA:BAYN) received a €124.00 ($147.62) target price from analysts at Berenberg Bank in a note issued to investors on Tuesday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Berenberg Bank’s price target indicates a potential upside of 18.72% from the stock’s previous close.
Several other equities research analysts also recently weighed in on the company. J P Morgan Chase & Co reissued a “buy” rating on shares of Bayer in a report on Wednesday, September 13th. Commerzbank set a €124.00 ($147.62) price objective on Bayer and gave the company a “buy” rating in a report on Wednesday, November 15th. Barclays set a €105.00 ($125.00) price objective on Bayer and gave the company a “sell” rating in a report on Friday, November 17th. UBS set a €125.00 ($148.81) price objective on Bayer and gave the company a “buy” rating in a report on Monday, November 6th. Finally, Goldman Sachs Group set a €125.00 ($148.81) target price on Bayer and gave the stock a “buy” rating in a report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of €122.19 ($145.46).
Bayer (FRA:BAYN) opened at €104.45 ($124.35) on Tuesday. Bayer has a 52 week low of €86.60 ($103.10) and a 52 week high of €123.82 ($147.40).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women?s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.